248 related articles for article (PubMed ID: 15297423)
1. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth.
Landen JW; Hau V; Wang M; Davis T; Ciliax B; Wainer BH; Van Meir EG; Glass JD; Joshi HC; Archer DR
Clin Cancer Res; 2004 Aug; 10(15):5187-201. PubMed ID: 15297423
[TBL] [Abstract][Full Text] [Related]
2. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma.
Landen JW; Lang R; McMahon SJ; Rusan NM; Yvon AM; Adams AW; Sorcinelli MD; Campbell R; Bonaccorsi P; Ansel JC; Archer DR; Wadsworth P; Armstrong CA; Joshi HC
Cancer Res; 2002 Jul; 62(14):4109-14. PubMed ID: 12124349
[TBL] [Abstract][Full Text] [Related]
3. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses.
Ke Y; Ye K; Grossniklaus HE; Archer DR; Joshi HC; Kapp JA
Cancer Immunol Immunother; 2000 Jul; 49(4-5):217-25. PubMed ID: 10941904
[TBL] [Abstract][Full Text] [Related]
4. Noscapine inhibits tumor growth in TMZ-resistant gliomas.
Jhaveri N; Cho H; Torres S; Wang W; Schönthal AH; Petasis NA; Louie SG; Hofman FM; Chen TC
Cancer Lett; 2011 Dec; 312(2):245-52. PubMed ID: 21925789
[TBL] [Abstract][Full Text] [Related]
5. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells.
Ye K; Ke Y; Keshava N; Shanks J; Kapp JA; Tekmal RR; Petros J; Joshi HC
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1601-6. PubMed ID: 9465062
[TBL] [Abstract][Full Text] [Related]
6. Noscapine, a Non-addictive Opioid and Microtubule-Inhibitor in Potential Treatment of Glioblastoma.
Altinoz MA; Topcu G; Hacimuftuoglu A; Ozpinar A; Ozpinar A; Hacker E; Elmaci İ
Neurochem Res; 2019 Aug; 44(8):1796-1806. PubMed ID: 31292803
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vitro cytotoxicity of haloderivatives of noscapine.
Verma AK; Bansal S; Singh J; Tiwari RK; Kasi Sankar V; Tandon V; Chandra R
Bioorg Med Chem; 2006 Oct; 14(19):6733-6. PubMed ID: 16784870
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death.
Aneja R; Vangapandu SN; Lopus M; Viswesarappa VG; Dhiman N; Verma A; Chandra R; Panda D; Joshi HC
Biochem Pharmacol; 2006 Aug; 72(4):415-26. PubMed ID: 16780803
[TBL] [Abstract][Full Text] [Related]
9. Determination of noscapine's localization and interaction with the tubulin-α/β heterodimer.
Alisaraie L; Tuszynski JA
Chem Biol Drug Des; 2011 Oct; 78(4):535-46. PubMed ID: 21781284
[TBL] [Abstract][Full Text] [Related]
10. Rational design of the microtubule-targeting anti-breast cancer drug EM015.
Aneja R; Lopus M; Zhou J; Vangapandu SN; Ghaleb A; Yao J; Nettles JH; Zhou B; Gupta M; Panda D; Chandra R; Joshi HC
Cancer Res; 2006 Apr; 66(7):3782-91. PubMed ID: 16585205
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine.
Zhou J; Gupta K; Yao J; Ye K; Panda D; Giannakakou P; Joshi HC
J Biol Chem; 2002 Oct; 277(42):39777-85. PubMed ID: 12183452
[TBL] [Abstract][Full Text] [Related]
12. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation.
Zhou J; Gupta K; Aggarwal S; Aneja R; Chandra R; Panda D; Joshi HC
Mol Pharmacol; 2003 Apr; 63(4):799-807. PubMed ID: 12644580
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.
Aneja R; Dhiman N; Idnani J; Awasthi A; Arora SK; Chandra R; Joshi HC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):831-9. PubMed ID: 17285314
[TBL] [Abstract][Full Text] [Related]
14. Antiglioma activity of curcumin-loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy.
Kundu P; Mohanty C; Sahoo SK
Acta Biomater; 2012 Jul; 8(7):2670-87. PubMed ID: 22484149
[TBL] [Abstract][Full Text] [Related]
15. 6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability.
Du S; Sarver JG; Trabbic CJ; Erhardt PW; Schroering A; Maltese WA
Cancer Chemother Pharmacol; 2019 Feb; 83(2):237-254. PubMed ID: 30426158
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of N-substituted noscapine analogues.
DeBono AJ; Xie JH; Ventura S; Pouton CW; Capuano B; Scammells PJ
ChemMedChem; 2012 Dec; 7(12):2122-33. PubMed ID: 23055449
[TBL] [Abstract][Full Text] [Related]
17. Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents.
Santoshi S; Manchukonda NK; Suri C; Sharma M; Sridhar B; Joseph S; Lopus M; Kantevari S; Baitharu I; Naik PK
J Comput Aided Mol Des; 2015 Mar; 29(3):249-70. PubMed ID: 25481458
[TBL] [Abstract][Full Text] [Related]
18. Rational design of novel anti-microtubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids.
Santoshi S; Naik PK; Joshi HC
J Biomol Screen; 2011 Oct; 16(9):1047-58. PubMed ID: 21972248
[TBL] [Abstract][Full Text] [Related]
19. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.
Abdalla MO; Karna P; Sajja HK; Mao H; Yates C; Turner T; Aneja R
J Control Release; 2011 Feb; 149(3):314-22. PubMed ID: 21047537
[TBL] [Abstract][Full Text] [Related]
20. Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitro.
Altinoz MA; Bilir A; Del Maestro RF; Tuna S; Ozcan E; Gedikoglu G
Surg Neurol; 2006 May; 65(5):478-84; discussion 485. PubMed ID: 16630910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
